On October 20, 2026 AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, reported company management will participate in three upcoming investor conferences in November.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

Guggenheim 3rd Annual Healthcare Innovation Conference, November 9-11, 2026

Eric Easom, Co-Founder, Chairman, President and CEO, will participate in a fireside chat on Monday, November 9, 2026 at 9:30am ET, and members of management will be available for 1X1 meetings.

Stifel 2026 Healthcare Conference, November 10-12, 2026

Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corporate overview on Tuesday, November 10, 2026 at 8:40am ET, and members of management will be available for 1X1 meetings.

Jefferies London Conference, November 16-19, 2026

Members of management will be available for 1X1 meetings on Tuesday, November 17, 2026.
Webcasts of the presentation and fireside chat can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

(Press release, AN2 Therapeutics, OCT 20, 2026, View Source [SID1234673627])